2022
Robotic Intracorporeal Neobladder: UCLH Experience
Weyne E, Tan W, Kelly J, Sridhar A. Robotic Intracorporeal Neobladder: UCLH Experience. 2022, 681-686. DOI: 10.1007/978-3-031-00363-9_60.Peer-Reviewed Original ResearchRobot-assisted radical cystectomyUniversity College London HospitalRadical cystectomyBladder cancerHigh-risk non-muscle-invasive bladder cancerTreatment of muscle-invasive bladder cancerNon-muscle-invasive bladder cancerMuscle-invasive bladder cancerRobotic radical cystectomyOrthotopic continent diversionPatient selectionContinent diversionCystectomyPostoperative careOperative techniqueNeobladder
2019
Effects of Bladder Cancer on UK Healthcare Costs and Patient Health-Related Quality of Life: Evidence From the BOXIT Trial
Cox E, Saramago P, Kelly J, Porta N, Hall E, Tan W, Sculpher M, Soares M. Effects of Bladder Cancer on UK Healthcare Costs and Patient Health-Related Quality of Life: Evidence From the BOXIT Trial. Clinical Genitourinary Cancer 2019, 18: e418-e442. PMID: 32144049, PMCID: PMC7427321, DOI: 10.1016/j.clgc.2019.12.004.Peer-Reviewed Original ResearchConceptsHealth-related quality of lifeNon-muscle-invasive bladder cancerMuscle-invasive bladder cancerProgression to muscle-invasive bladder cancerQuality of lifePatients' health-related quality of lifePatients' health-related qualityBladder cancerHealth-related qualityEQ-5D-3LGeneralized estimating equationsUK unit costsRandomized controlled trialsHRQoL decrementNon-muscle-invasive bladder cancer patientsHRQoLHealthcare costsHRQOL effectsLimited evidenceControlled trialsEstimating equationsTMN classificationClinical eventsAverage costRecurrence
2018
Does urinary cytology have a role in haematuria investigations?
Tan W, Sarpong R, Khetrapal P, Rodney S, Mostafid H, Cresswell J, Watson D, Rane A, Hicks J, Hellawell G, Davies M, Srirangam S, Dawson L, Payne D, Williams N, Brew‐Graves C, Feber A, Kelly J, Sridhar A, Lamb B, Ocampo F, McBain H, Baillie K, Middleton K, Knight H, Maher S, Pathmanathan B, Harmathova A, Pelluri S, Pati J, Cossons A, Scott C, Madaan S, Bradfield S, Wakeford N, Dann, Cook J, Cornwell M, Mills R, Thomas, Reyner S, Vallejera G, Adeniran P, Masood S, Whotton N, Dent K, Pearson S, Hatton J, Newton M, Hheeney E, Green K, Evans S, Rogers M, Gupwell K, ley S, Brown A, McGrath J, Lunt N, Hill P, inclair A, Paredes‐Guerra A, Holbrook B, Ong E, Wardle H, Wilson D, Bayles A, Fennelly R, Tribbeck M, Ames K, Taylor J, Edmunds E, Moore J, Mckinley S, Nolan T, peed A, Tunnicliff A, Fossey G, Williams A, George M, Hutchins I, Einosas R, Richards A, Henderson A, Appleby B, Kehoe L, Gladwell L, Drakeley S, Davies J, Krishnan R, Roberts H, Main C, Jain S, Dumville J, Wilkinson N, Taylor J, Thomas F, Goulden K, Vinod C, Green E, Waymont C, Rogers J, Grant A, Carter V, Heap H, Lomas C, Cooke P, Scarratt L, Hodgkiss T, Johnstone D, Johnson J, Allsop J, Rothwell J, Connolly K, Cherian J, Ridgway S, Coulding M, Savill H, Mccormick J, Clark M, Collins G, Jewers K, Keith S, Bowen G, Hargreaves J, Riley K, Rees A, Williams S, Dukes S, Goffe A, Mistry R, Chadwick J, Cocks S, Hull R, oftus A, Baird Y, Moore S, Greenslade S, Margalef J, Chadbourn I, Harris M, Clitheroe P, Connolly S, Hodgkinson S, Haydock H, Storr E, Cogley L, Natale S, Lovegrove W, Slack K, Nash D, Smith K, Walsh J, Guerdette A, Hill M, Taylor B, Sinclair E, Perry M, Debbarma M, Hewitt D, Sriram R, Power A, Cannon J, Devereaux L, Thompson A, Atkinson K, Royle L, Madine J, MacLean K. Does urinary cytology have a role in haematuria investigations? BJU International 2018, 123: 74-81. PMID: 30003675, PMCID: PMC6334509, DOI: 10.1111/bju.14459.Peer-Reviewed Original ResearchMeSH KeywordsAgedCarcinoma, Transitional CellFalse Negative ReactionsFalse Positive ReactionsFemaleHematuriaHumansKidney NeoplasmsMaleMiddle AgedNeoplasm GradingNeoplasm StagingPredictive Value of TestsProspective StudiesTomography, X-Ray ComputedUltrasonographyUreteral NeoplasmsUrinary Bladder NeoplasmsUrineUrographyConceptsUpper tract urothelial cancerPositive urine cytologyAccuracy of urinary cytologyDiagnosis of bladder cancerUrine cytologyHigh-risk cancerNegative predictive valuePositive predictive valueBladder cancerHaematuria investigationsUrinary cytologyInvasive testingDiagnostic accuracy of urinary cytologyMuscle-invasive bladder cancerProspective observational study of patientsMulticentre prospective observational studyObservational study of patientsPredictive valueEndoscopic tumor resectionPositive cytology resultsUpper tract imagingHigh-risk diseaseOutcomes of patientsDiagnosed bladder cancerStudy of patients
2017
UroMark—a urinary biomarker assay for the detection of bladder cancer
Feber A, Dhami P, Dong L, de Winter P, Tan W, Martínez-Fernández M, Paul D, Hynes-Allen A, Rezaee S, Gurung P, Rodney S, Mehmood A, Villacampa F, de la Rosa F, Jameson C, Cheng K, Zeegers M, Bryan R, James N, Paramio J, Freeman A, Beck S, Kelly J. UroMark—a urinary biomarker assay for the detection of bladder cancer. Clinical Epigenetics 2017, 9: 8. PMID: 28163793, PMCID: PMC5282868, DOI: 10.1186/s13148-016-0303-5.Peer-Reviewed Original ResearchConceptsDetection of bladder cancerEpigenetic alterationsSequencing assayNovel high-throughputBladder cancerBackgroundBladder cancerNext-generation sequencing assayUrinary biomarkersDNA methylationMuscle-invasive bladder cancerUrinary biomarker assaysSediment DNAAnalysis pipelineVoided urine samplesDetection of BCPrimary BCHigh-throughputCystoscopic examinationVoided urineDNAIndependent cohortAssayBiomarker panelDiagnosed BCCancer
2016
Port-Site Metastases After Robotic Radical Cystectomy: A Systematic Review and Management Options
Khetrapal P, Tan W, Lamb B, Nathan S, Briggs T, Shankar A, Ramachandran N, Freeman A, Mitra A, Kelly J. Port-Site Metastases After Robotic Radical Cystectomy: A Systematic Review and Management Options. Clinical Genitourinary Cancer 2016, 15: 440-444. PMID: 28209455, DOI: 10.1016/j.clgc.2016.06.012.Peer-Reviewed Original ResearchConceptsRobot-assisted radical cystectomyPort-site metastasisRadical cystectomyCase of port-site metastasisLymph node-positive diseaseMuscle-invasive bladder cancerIntracorporeal robot-assisted radical cystectomySystematic reviewNode-positive diseaseSystematic review of MEDLINERobotic radical cystectomyIdentified 4 casesTreatment of chemotherapyReview of MEDLINEDisease-free statusSalvage chemotherapyPrimary tumorSurgical excisionMultimodal treatmentPublished studiesAggressive treatmentBladder cancerTreatment optionsEmbase databasesPatient factors
2015
Robot‐assisted intracorporeal pyramid neobladder
Tan W, Sridhar A, Goldstraw M, Zacharakis E, Nathan S, Hines J, Cathcart P, Briggs T, Kelly J. Robot‐assisted intracorporeal pyramid neobladder. BJU International 2015, 116: 771-779. PMID: 26033321, DOI: 10.1111/bju.13189.Peer-Reviewed Original ResearchConceptsRobot-assisted radical cystectomyMuscle-invasive bladder cancerUrinary tract infectionPostoperative complicationsFunctional outcomesMedian estimated blood lossNight time continenceBilateral pelvic lymphadenectomyEstimated blood lossMedian hospital stayRecurrence-free survivalUpper tract imagingMedian follow-upLate postoperative complicationsEarly postoperative complicationsPort-site herniaUretero-ileal strictureVitamin B12 deficiencyBlocked stentsNeobladder stonePelvic lymphadenectomyOncological outcomesRadical cystectomyOverall survivalBlood loss
2014
Management of Node-Positive Bladder Cancer After Neoadjuvant Chemotherapy and Radical Cystectomy: A Survey of Current UK Practice
Tan W, Lamb B, Payne H, Hughes S, Green J, Lane T, Adshead J, Boustead G, Vasdev N. Management of Node-Positive Bladder Cancer After Neoadjuvant Chemotherapy and Radical Cystectomy: A Survey of Current UK Practice. Clinical Genitourinary Cancer 2014, 13: e153-e158. PMID: 25510376, DOI: 10.1016/j.clgc.2014.11.006.Peer-Reviewed Original ResearchConceptsNeoadjuvant chemotherapy regimenNeoadjuvant chemotherapyPositive lymph nodesRadical cystectomyAdjuvant chemotherapyTreatment of patientsBladder cancerNodal diseaseLymph nodesIndication of adjuvant chemotherapyNode-positive bladder cancerPresence of disease progressionResponse to NACCancer CenterMuscle-invasive bladder cancerCycles of gemcitabineAdvanced bladder cancerPatient performance statusUro-oncologistsChemotherapy regimenPerformance statusLack of published evidenceDisease progressionChemotherapyPatientsLoss of expression of the tumour suppressor gene AIMP3 predicts survival following radiotherapy in muscle‐invasive bladder cancer
Gurung P, Veerakumarasivam A, Williamson M, Counsell N, Douglas J, Tan W, Feber A, Crabb S, Short S, Freeman A, Powles T, Hoskin P, West C, Kelly J. Loss of expression of the tumour suppressor gene AIMP3 predicts survival following radiotherapy in muscle‐invasive bladder cancer. International Journal Of Cancer 2014, 136: 709-720. PMID: 24917520, DOI: 10.1002/ijc.29022.Peer-Reviewed Original ResearchConceptsMuscle-invasive bladder cancerMuscle-invasive bladder cancer patientsTissue-microarrayBladder cancerAssociated with survivalPredictive of survivalMethylation-specific PCRColony forming assayLoss of expressionRadical cystectomyRadiotherapy trialsRadiosensitising effectPrognostic valueMechanism of gene silencingRadiotherapyResponse to ionising radiationClinical biomarkersPatientsProtein expressionCancerMeta-analysisDNA damage responseCystectomySurvivalBladder